UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of November 2026
Commission
File Number: 001-41950
Ryde
Group Ltd
Duo
Tower, 3 Fraser Street, #08-21
Singapore
189352
+65-9665-3216
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Information
contained in this Report on Form 6-K
Director
Appointment
On
November 13, 2026, the Board appointed Dr. Chen Chong (“Dr. Chen”) as an independent director, as chairman of the nominations
committee, and as a member of each of the audit committee and the compensation committee of the Board. Dr. Chen is currently an Associate
Professor of Finance and Associate Dean of the Chinese Academy of Finance and Development at the Central University of Finance and Economics
in Beijing, and has served as Chief Economist of Ueda Yagi Money Broking (China) Co., Ltd. since January 2024, where he leads macro-economic,
bond market and inter-bank market research. Since August 2025, Dr. Chen has served as an independent director of Barentsz Capital Limited,
where he chairs the audit committee and is a member of each of the compensation committee and the nomination committee. His research
in corporate finance, capital structure, mergers and acquisitions and corporate governance has been published in leading journals, including
the Journal of Corporate Finance and the Journal of Business Ethics. Dr. Chen holds a Ph.D. and an M.Phil. in Finance from City University
of Hong Kong, a B.A. in Economics from Peking University and a B.S. in Applied Mathematics from the Communication University of China.
The Company believes that Dr. Chen’s expertise in corporate finance and governance, together with his board committee experience,
will bring significant value to the Company.
On
November 13, 2026, the Board appointed Mr. Suen Wai Hin (“Mr. Vincent Suen”) as an independent director, as chairman of the
audit committee, and as a member of each of the compensation committee and the nominations committee of the Board. Mr. Vincent Suen is
currently the Founder and Managing Director of Cypress Corporate Advisory Limited, which provides accounting and financial reporting,
auditing, internal control, company secretarial and governance advisory services to listed and private companies in Hong Kong and the
PRC. From June 2018 to May 2023, he served as Chief Financial Officer and company secretary of Orange Tour Cultural Holding Limited (HKEX:
8627), where he led the execution of its initial public offering and oversaw its financial reporting. Prior to that, Mr. Vincent Suen
spent over seven years with Deloitte Touche Tohmatsu, where he led audits of listed companies as well as IPO and M&A engagements.
He is a Certified Public Accountant (CPA Australia) and a member of The Hong Kong Chartered Governance Institute, and holds a Bachelor
of Commerce from The University of Sydney and a Master of Corporate Governance from The Hong Kong Polytechnic University. The Company
believes that Mr. Vincent Suen’s audit, financial reporting and listed company governance experience will bring significant value
to the Company.
Neither
Dr. Chen nor Mr. Vincent Suen has any family relationship with any director or executive officer of the Company, or holds any equity
interest in the Company. Dr. Chen serves as an independent director of Barentsz Capital Limited (“Barentsz”), which holds
40% of the issued shares of RGT (BVI) Ltd, an entity in which the Company holds the remaining 60%. Dr. Chen does not hold any executive
position or equity interest in Barentsz or RGT (BVI) Ltd, and any interest he may have in dealings between the Company and Barentsz or
RGT (BVI) Ltd arises solely from his position as a non-executive director of Barentsz. Except as disclosed above, there are no transactions
between the Company and either Dr. Chen or Mr. Vincent Suen that would be required to be disclosed under Item 7.B of Form 20-F. The Board
has determined that each of Dr. Chen and Mr. Vincent Suen is independent within the meaning of Section 803A of the NYSE American Company
Guide and meets the independence requirements of Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and that Mr. Vincent
Suen qualifies as an “audit committee financial expert” as defined in Item 16A of Form 20-F.
Director
Departure
On
November 13, 2026, Ms. KHOO Su Nee Joanne and Mr. Venkata Subramanian s/o SREENIVASAN each resigned as a member of the board of directors
(the “Board”) of Ryde Group Ltd (the “Company”) and from the audit committee, compensation committee and nominations
committee of the Board. Ms. Khoo served as chairman of the audit committee and Mr. Sreenivasan served as chairman of the nominations
committee. Neither resignation is the result of any disagreement with the Company on any matter relating to its operations, policies
or practices. The Company thanks Ms. Khoo and Mr. Sreenivasan for their service and contributions to the Board.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Ryde
Group Ltd |
| |
|
|
| Date:
November 13, 2026 |
By: |
/s/
Zou Junming Terence |
| |
Name: |
Zou
Junming Terence |
| |
Title: |
Chairman
of the Board of Directors and Chief Executive Officer |
